D.E. Shaw & Co
VIR icon

D.E. Shaw & Co’s Vir Biotechnology VIR Stock Holding History

D.E. Shaw & Co’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.24M Sell
416,403
-401,282
-49% -$3.82M ﹤0.01% 2536
2026
Q1 		$7.33M Buy
817,685
+767,893
+1,542% +$6.12M ﹤0.01% 1876
2025
Q4 		$300K Buy
49,792
+16,268
+49% +$96.9K ﹤0.01% 4151
2025
Q3 		$191K Sell
33,524
-2,733
-8% -$14K ﹤0.01% 4293
2025
Q2 		$183K Sell
36,257
-470,447
-93% -$2.52M ﹤0.01% 4067
2025
Q1 		$3.28M Buy
506,704
+4,704
+0.9% +$41.8K ﹤0.01% 2217
2024
Q4 		$3.68M Sell
502,000
-428,655
-46% -$3.38M ﹤0.01% 2235
2024
Q3 		$6.97M Buy
930,655
+8,101
+0.9% +$70.4K 0.01% 1680
2024
Q2 		$8.21M Buy
922,554
+276,300
+43% +$2.65M 0.01% 1464
2024
Q1 		$6.55M Sell
646,254
-122,890
-16% -$1.25M 0.01% 1682
2023
Q4 		$7.74M Sell
769,144
-111,087
-13% -$1.02M 0.01% 1572
2023
Q3 		$8.25M Buy
880,231
+826,696
+1,544% +$11.8M 0.01% 1421
2023
Q2 		$1.31M Sell
53,535
-13,765
-20% -$346K ﹤0.01% 2922
2023
Q1 		$1.57M Buy
67,300
+22,305
+50% +$570K ﹤0.01% 2860
2022
Q4 		$1.14M Buy
44,995
+30,177
+204% +$740K ﹤0.01% 3353
2022
Q3 		$286K Buy
14,818
+6,230
+73% +$158K ﹤0.01% 4321
2022
Q2 		$219K Sell
8,588
-43,642
-84% -$1.02M ﹤0.01% 4510
2022
Q1 		$1.34M Sell
52,230
-92,572
-64% -$2.75M ﹤0.01% 3665
2021
Q4 		$6.06M Sell
144,802
-22,324
-13% -$875K 0.01% 2175
2021
Q3 		$7.27M Sell
167,126
-52,102
-24% -$2.26M 0.01% 1777
2021
Q2 		$10.4M Buy
219,228
+102,936
+89% +$4.68M 0.01% 1466
2021
Q1 		$5.96M Buy
116,292
+94,721
+439% +$5.1M 0.01% 1721
2020
Q4 		$578K Buy
+21,571
New +$701K ﹤0.01% 3321

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co's VIR Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Vir Biotechnology (VIR) stake by 49% in Q2 2026, selling an estimated $3.82M and leaving 416,403 shares worth $4.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

D.E. Shaw & Co first reported a position in VIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $10.4M in Q2 2021. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • D.E. Shaw & Co held 416,403 shares of Vir Biotechnology worth $4.24M as of Q2 2026.
  • D.E. Shaw & Co sold 401,282 Vir Biotechnology shares in Q2 2026, an estimated $3.82M.
  • Vir Biotechnology made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2536 holding.
  • D.E. Shaw & Co first reported a position in Vir Biotechnology in Q4 2020 and has held it in 23 quarters since.
  • D.E. Shaw & Co's Vir Biotechnology position peaked at $10.4M in Q2 2021.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.